Therefore, we aimed to build on these data by describing the global accessibility and reimbursement of diabetes technologies and insulin for children with T1D in countries actively participating in the SWEET initiative and to compare these data with glycemic control as measured by glycated hemoglobin (HbA1c) levels using the data from the SWEET registry. Here, INS is linked to diabetes mellitus.